Intravenous Iron and SGLT2 Inhibitors in Iron-Deficient Patients with Heart Failure and Reduced Ejection Fraction
Open Access
- 28 March 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 11 (4) , 1875-1879
Abstract
Aims: To explore the potential interaction between use of SGLT2 inhibitors and the increase in haemoglobin in patients randomized to intravenous iron or the control group in the IRONMAN (Effectiveness of Intravenous Iron Treatment versus Standard Care in Patients with Heart Failure and Iron Deficiency) trial. Methods and results: This was a post hoc exploratory analysis of the IRONMAN trial which randomized patients with heart failure, a left ventricular ejection fraction (LVEF) ≤ 45% and iron deficiency (transferrin saturation 16 g/dL [women]). Conclusions: In the IRONMAN trial, there was a trend to a greater increase in haemoglobin with ferric derisomaltose in iron-deficient patients taking an SGLT2 inhibitor at baseline, as compared with those not taking one.Keywords
Funding Information
- British Heart Foundation (CS/15/1/3117)
- British Heart Foundation (CS/15/1/31175)
- British Heart Foundation Centre of Research Excellence Grant (RE/18/6/34217)
- British Heart Foundation (CS/15/1/3117)
- British Heart Foundation (CS/15/1/31175)
This publication has 11 references indexed in Scilit:
- Erythropoietic Response After Intravenous Iron in Patients with Heart Failure and Reduced Ejection Fraction with and Without Background Treatment with Sodium–Glucose Cotransporter 2 InhibitorsEuropean Journal of Heart Failure, 2023
- Intravenous Iron in Patients with Heart Failure and Iron Deficiency: An Updated Meta-AnalysisEuropean Journal of Heart Failure, 2023
- Combining Iron Supplements With SGLT2 Inhibitor-Stimulated Erythropoiesis in Heart Failure: Should We Be Worried About Thromboembolic Events?Journal of Cardiac Failure, 2022
- Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trialThe Lancet, 2022
- Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart FailureJACC: Heart Failure, 2022
- Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HFCirculation, 2022
- Rationale and design of a randomised trial of intravenous iron in patients with heart failureHeart, 2022
- Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and DesignCirculation: Heart Failure, 2021
- Effect of dapagliflozin on anaemia in DAPA‐HFEuropean Journal of Heart Failure, 2021
- Treatment of Anemia with Darbepoetin Alfa in Systolic Heart FailureNew England Journal of Medicine, 2013